Effects of Switching to Netarsudil/Latanoprost Fixed Dose Combination from Various Latanoprost Regimens: The Phase 4 MORE Study
Jason Bacharach,1 Ehsan Sadri,2 Gagan Sawhney,3 Casey Kopczynski,4 Mohinder M Merchea4 1North Bay Eye Associates, Inc, Petaluma, CA, USA; 2Visionary Eye Institute, Newport Beach, CA, USA; 3Georgia Eye Partners, Atlanta, GA, USA; 4Alcon, Inc, Fort Worth, TX, USACorrespondence: Jason Bacharach, North...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2025-01-01
|
| Series: | Clinical Ophthalmology |
| Subjects: | |
| Online Access: | https://www.dovepress.com/effects-of-switching-to-netarsudillatanoprost-fixed-dose-combination-f-peer-reviewed-fulltext-article-OPTH |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832592043291967488 |
|---|---|
| author | Bacharach J Sadri E Sawhney G Kopczynski C Merchea MM |
| author_facet | Bacharach J Sadri E Sawhney G Kopczynski C Merchea MM |
| author_sort | Bacharach J |
| collection | DOAJ |
| description | Jason Bacharach,1 Ehsan Sadri,2 Gagan Sawhney,3 Casey Kopczynski,4 Mohinder M Merchea4 1North Bay Eye Associates, Inc, Petaluma, CA, USA; 2Visionary Eye Institute, Newport Beach, CA, USA; 3Georgia Eye Partners, Atlanta, GA, USA; 4Alcon, Inc, Fort Worth, TX, USACorrespondence: Jason Bacharach, North Bay Eye Associates, Inc, 104 Lynch Creek Way, Suite 15, Petaluma, CA, USA, Tel +1(707) 762-3573, Fax +1 (707) 762-6873, Email jbacharach@northbayeye.comPurpose: To determine the effect on intraocular pressure (IOP) of switching to a once-daily netarsudil/latanoprost fixed dose combination (FDC) from various topical treatment regimens including latanoprost monotherapy or latanoprost combined with other IOP-lowering agents for the treatment of open-angle glaucoma or ocular hypertension.Methods: A total of 136 participants enrolled. Eligible participants were aged ≥ 18 years and had a current diagnosis of open-angle glaucoma or ocular hypertension. Additional inclusion criteria were current treatment regimens with latanoprost monotherapy, latanoprost plus 1 additional IOP-lowering agent, or latanoprost plus 2 agents; current IOP-lowering regimen stable for ≥ 30 days prior to baseline visit; treated morning IOP ≥ 20 mmHg at baseline visit; and best corrected visual acuity (BCVA) of 20/100 or better in both eyes. Regardless of their initial regimens, all participants stopped their IOP-lowering medication(s) and were switched directly to netarsudil/latanoprost FDC alone.Results: Participants experienced substantial reductions in IOP. At week 12, the mean percent change from baseline in IOP was − 18.5% (SD 18.96) in the overall study population and was similar in the latanoprost monotherapy group (− 21.2% [SD 17.46]), the latanoprost +1 agent group (− 15.7% [SD 21.91]), and the latanoprost +2 agents group (− 16.9% [SD 17.31]). Less than one-third of participants (31.6%) experienced any ocular adverse event or an ocular adverse event related to treatment (27.2%). The most common ocular adverse event was conjunctival hyperemia (18.4%). Most ocular adverse events were mild, and two severe ocular adverse events of hyperemia (1.5%) were reported; no serious ocular adverse events were reported.Conclusion: In this study, additional IOP lowering was achievable when patients switched to netarsudil/latanoprost FDC after treatment with latanoprost alone or latanoprost with 1 or 2 additional agents. The once-daily administration of netarsudil/latanoprost FDC and reduced treatment burden for those on latanoprost combined with additional agents may prove more manageable for patients.Keywords: glaucoma, intraocular pressure, prostaglandin analog, rho-kinase inhibitor |
| format | Article |
| id | doaj-art-00589d1a34f14672a4ab0c005d7a820c |
| institution | Kabale University |
| issn | 1177-5483 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Clinical Ophthalmology |
| spelling | doaj-art-00589d1a34f14672a4ab0c005d7a820c2025-01-21T16:58:07ZengDove Medical PressClinical Ophthalmology1177-54832025-01-01Volume 1917518699432Effects of Switching to Netarsudil/Latanoprost Fixed Dose Combination from Various Latanoprost Regimens: The Phase 4 MORE StudyBacharach JSadri ESawhney GKopczynski CMerchea MMJason Bacharach,1 Ehsan Sadri,2 Gagan Sawhney,3 Casey Kopczynski,4 Mohinder M Merchea4 1North Bay Eye Associates, Inc, Petaluma, CA, USA; 2Visionary Eye Institute, Newport Beach, CA, USA; 3Georgia Eye Partners, Atlanta, GA, USA; 4Alcon, Inc, Fort Worth, TX, USACorrespondence: Jason Bacharach, North Bay Eye Associates, Inc, 104 Lynch Creek Way, Suite 15, Petaluma, CA, USA, Tel +1(707) 762-3573, Fax +1 (707) 762-6873, Email jbacharach@northbayeye.comPurpose: To determine the effect on intraocular pressure (IOP) of switching to a once-daily netarsudil/latanoprost fixed dose combination (FDC) from various topical treatment regimens including latanoprost monotherapy or latanoprost combined with other IOP-lowering agents for the treatment of open-angle glaucoma or ocular hypertension.Methods: A total of 136 participants enrolled. Eligible participants were aged ≥ 18 years and had a current diagnosis of open-angle glaucoma or ocular hypertension. Additional inclusion criteria were current treatment regimens with latanoprost monotherapy, latanoprost plus 1 additional IOP-lowering agent, or latanoprost plus 2 agents; current IOP-lowering regimen stable for ≥ 30 days prior to baseline visit; treated morning IOP ≥ 20 mmHg at baseline visit; and best corrected visual acuity (BCVA) of 20/100 or better in both eyes. Regardless of their initial regimens, all participants stopped their IOP-lowering medication(s) and were switched directly to netarsudil/latanoprost FDC alone.Results: Participants experienced substantial reductions in IOP. At week 12, the mean percent change from baseline in IOP was − 18.5% (SD 18.96) in the overall study population and was similar in the latanoprost monotherapy group (− 21.2% [SD 17.46]), the latanoprost +1 agent group (− 15.7% [SD 21.91]), and the latanoprost +2 agents group (− 16.9% [SD 17.31]). Less than one-third of participants (31.6%) experienced any ocular adverse event or an ocular adverse event related to treatment (27.2%). The most common ocular adverse event was conjunctival hyperemia (18.4%). Most ocular adverse events were mild, and two severe ocular adverse events of hyperemia (1.5%) were reported; no serious ocular adverse events were reported.Conclusion: In this study, additional IOP lowering was achievable when patients switched to netarsudil/latanoprost FDC after treatment with latanoprost alone or latanoprost with 1 or 2 additional agents. The once-daily administration of netarsudil/latanoprost FDC and reduced treatment burden for those on latanoprost combined with additional agents may prove more manageable for patients.Keywords: glaucoma, intraocular pressure, prostaglandin analog, rho-kinase inhibitorhttps://www.dovepress.com/effects-of-switching-to-netarsudillatanoprost-fixed-dose-combination-f-peer-reviewed-fulltext-article-OPTHglaucomaintraocular pressureprostaglandin analogrho-kinase inhibitor |
| spellingShingle | Bacharach J Sadri E Sawhney G Kopczynski C Merchea MM Effects of Switching to Netarsudil/Latanoprost Fixed Dose Combination from Various Latanoprost Regimens: The Phase 4 MORE Study Clinical Ophthalmology glaucoma intraocular pressure prostaglandin analog rho-kinase inhibitor |
| title | Effects of Switching to Netarsudil/Latanoprost Fixed Dose Combination from Various Latanoprost Regimens: The Phase 4 MORE Study |
| title_full | Effects of Switching to Netarsudil/Latanoprost Fixed Dose Combination from Various Latanoprost Regimens: The Phase 4 MORE Study |
| title_fullStr | Effects of Switching to Netarsudil/Latanoprost Fixed Dose Combination from Various Latanoprost Regimens: The Phase 4 MORE Study |
| title_full_unstemmed | Effects of Switching to Netarsudil/Latanoprost Fixed Dose Combination from Various Latanoprost Regimens: The Phase 4 MORE Study |
| title_short | Effects of Switching to Netarsudil/Latanoprost Fixed Dose Combination from Various Latanoprost Regimens: The Phase 4 MORE Study |
| title_sort | effects of switching to netarsudil latanoprost fixed dose combination from various latanoprost regimens the phase 4 more study |
| topic | glaucoma intraocular pressure prostaglandin analog rho-kinase inhibitor |
| url | https://www.dovepress.com/effects-of-switching-to-netarsudillatanoprost-fixed-dose-combination-f-peer-reviewed-fulltext-article-OPTH |
| work_keys_str_mv | AT bacharachj effectsofswitchingtonetarsudillatanoprostfixeddosecombinationfromvariouslatanoprostregimensthephase4morestudy AT sadrie effectsofswitchingtonetarsudillatanoprostfixeddosecombinationfromvariouslatanoprostregimensthephase4morestudy AT sawhneyg effectsofswitchingtonetarsudillatanoprostfixeddosecombinationfromvariouslatanoprostregimensthephase4morestudy AT kopczynskic effectsofswitchingtonetarsudillatanoprostfixeddosecombinationfromvariouslatanoprostregimensthephase4morestudy AT mercheamm effectsofswitchingtonetarsudillatanoprostfixeddosecombinationfromvariouslatanoprostregimensthephase4morestudy |